Vimarsana
Biggest News Aggregation in the World

Page 30 - Mark Crossley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Crossley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Crossley Today - Breaking & Trending Today

Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants - Vimarsana News

Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

/PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of data from a clinical pharmacology study designed to assess the ability of...

A cheap UK growth stock to buy right now - Vimarsana News

A cheap UK growth stock to buy right now

This business is emerging from a troubled period but growth looks set to be a feature in the years ahead. There are risks, but here's why I've bought the stock.

Source: fool.co.uk
I'm not kidding, we could win this!Islington Tribune - Vimarsana News

I'm not kidding, we could win this!Islington Tribune

OPINION: Anything is possible in the FA Cup – and for some clubs the third round is still a big deal

Investegate |Indivior PLC Announcements | Indivior PLC: 3rd Quarter Results - Vimarsana News

Investegate |Indivior PLC Announcements | Indivior PLC: 3rd Quarter Results

Investegate announcements from Indivior PLC, 3rd Quarter Results

Investegate |Indivior PLC Announcements | Indivior PLC: Half-year Report - Vimarsana News

Investegate |Indivior PLC Announcements | Indivior PLC: Half-year Report

This Release Contains Inside Information. Comment by Mark Crossley, CEO of Indivior PLC "The second quarter saw Indivior make good progress against our Strategic Priorities and deliver strong performance, including our fourth consecutive quarter of double-digit growth from SUBLOCADE® (buprenorphine extended-release) injection. Based on the momentum in the business, we raised our FY 2021 guidance at the end of the quarter. Looking forward, our number one priority continues to be capturing the full transformational value of SUBLOCADE, and it is gratifying to see furthe...